Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Colorimetric Test Devised for Tuberculosis in Developing Areas

By LabMedica International staff writers
Posted on 28 Dec 2015
A rapid, sensitive and low-cost method has been devised for detecting tuberculosis (TB), a highly infectious disease and a major global health problem, especially in countries with developing health care systems. More...


The typical way that physicians screen for TB, which is caused by the bacterium Mycobacterium tuberculosis (Mtb), is with a tuberculin skin test or an examination of a patient's sputum under a microscope. To weed out false positives, a more reliable test that involves growing Mtb cultures can be performed, but that requires weeks to complete.

Scientists at the Australian Institute for Bioengineering and Nanotechnology (St Lucia, QLD, Australia) and their colleagues began with a newly created nucleic acid amplification test that does not require expensive laboratory equipment to detect Mtb, but this modified test typically uses costly fluorescence technology to read the results. The team substituted the fluorescence detector with a colorimetric assay that changes to a blue hue if the infection is present, allowing health care workers to identify positive test results right away with the naked eye.

The team employed a modified Solid Phase Reversible Immobilization (SPRI) protocol) with Guanidium-HCl lysis buffer to sample for genomic DNA (gDNA) from Mtb cells. Nucleic acid amplification was performed with the TwistAmp Basic RPA Kit (TwistDx Limited; Cambridge, UK). They devised a simple colorimetric assay that utilizes the chemical oxidation of 3,3′,5,5′-tetramethylbenzidine (TMB) by isothermally functionalized DNA targets as a sensitive and specific biosensor for the detection of tuberculosis. Absorbance was determined with the ND-1000spectrophotometer (NanoDrop; Wilmington, DE, USA). Ampometry responses were measured on a workstation potentiostat (CH Instruments; Austin, TX, USA).

The team demonstrated how the modified diagnostic could be put on cheap, disposable electrochemical sensors for increased sensitivity, even in the field. Because the assay is inexpensive, quick and highly specific for the Mtb bacterium, the scientists say it could have a big impact in low-resource communities. The assays are inexpensive at USD 3.00, takes only 75 minutes, sensitive as approaching a single cell, and highly specific to M. tuberculosis. The study was published on November 30, 2015, in the journal ACS Sensors.

Related Links:

Australian Institute for Bioengineering and Nanotechnology 
TwistDx Limited 
NanoDrop



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.